Variable
Sexe, n (%) Male
62 (53%)
Median age, years (range) 52 (17 – 83)
Age, n (%) ≥ 70 years
13 (11%)
Performance status, n (%) 0-1 ≥ 2 89 (75%) 29 (25%)
Body Mass Index, n (%) < 25 ≥ 25 64 (54%) 54 (46%)
Primitive, n (%) Soft tissue sarcoma Bone sarcoma 95 (81%) 23 (19%)
Subtypes, n (%) Leiomyosarcoma Synovial sarcoma Malignant solitary fibrous tumour Epithelioid and clear cell sarcoma Myxofibrosarcoma Undifferentiated pleomorphic and fusiform cell sarcoma Others* 28 (30%) 14 (15%) 12 (13%) 8 (9%) 7 (8%) 6 (6%) 13 (13%)
Site of primitive tumour, n (%) Lower member Upper member Trunk (thorax, abdomen, head and neck) Uterus 43 (45%) 11 (11%) 30 (32%) 11 (11%)
Histological grade, n (%) 1 2 3 Not concerned** 4 (4%) 27 (29%) 40 (42%) 24 (25%)
Pazopanib metastatic line, n (%) First Second ≥ Third 31 (26%) 44 (37%) 43 (37%)
Initial daily dose of pazopanib, n (%) 200 mg 400 mg 600 mg 800 mg 2 (2%) 17 (14%) 30 (25%) 69 (59%)
Albumin, n (%) < 35 ≥ 35 17 (14%) 101 (86%)
SGOT - SGPT, n (%) ≤ ULN (≤ 40) > ULN (> 40) 97 (82%) 21 (18%)
C Reactive Protein, n (%) < 10 ≥ 10 NA 72 (61%) 43 (37%) 3 (2%)
Neutrophils/Lymphocytes Ratio (NLR) < 3.5 ≥ 3.5 70 (59%) 48 (41%)